Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2020-04-27 Capital/Financing Update
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated April 27, 2020, for Lyra Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed prospectus information such as risk factors, use of proceeds, capitalization, dilution, management discussion and analysis, business overview, executive compensation, principal stockholders, underwriting, and legal matters. This is characteristic of a registration statement filing, specifically Form S-1, which is a capital markets filing related to securities registration and offering, not a financial report or earnings release. According to the provided filing definitions, none explicitly mention Form S-1 or registration statements. The closest relevant category is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. Since this document is a registration statement for an IPO, it fits best under Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the appropriate classification is CAP with high confidence.
2020-04-27 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It specifically registers the common stock of Lyra Therapeutics, Inc. on The Nasdaq Stock Market. The document includes details about the securities to be registered and references a prior S-1 registration statement. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to securities registration. Given the nature of Form 8-A filings, this fits best under Regulatory Filings (RNS). The document length is short and it is a formal SEC filing, not an announcement or report publication. Therefore, the classification is RNS with high confidence.
2020-04-27 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 for Lyra Therapeutics, Inc. It discusses the anticipated IPO price range, stock option grants, and valuation analyses related to the company's common stock. The content is focused on the IPO process and related disclosures rather than a full financial report or earnings release. The document is not a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a proxy statement, voting results, or management change announcement. The document is a correspondence related to a registration statement for an IPO, which is a regulatory filing. It does not contain financial statements or comprehensive financial data but rather detailed information supporting the registration statement and confidential treatment requests. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-04-24 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities for sale to the public. It includes detailed information about the company, its business, risk factors, management, financial data, and the offering itself. This type of filing is neither an annual report, earnings release, nor any other report type listed. It is a capital markets filing related to the company's initial public offering and registration of securities. According to the provided filing categories, the closest and most appropriate classification is 'Capital/Financing Update' (CAP), which covers updates on company fundraising and financing activities, including IPO registration statements like Form S-1.
2020-03-06 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for Lyra Therapeutics, Inc. It is an initial public offering (IPO) prospectus, which includes detailed information about the company, its business, risk factors, management, financial data, and the offering of common stock to the public. The presence of the SEC form type 'S-1' and the description of the offering, underwriting, and registration fee calculation clearly identify this as a registration statement for securities offering, not a financial report or other filing type. This type of document is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and compliance document related to securities registration and offering, which does not fit into other specific categories like Annual Report or Earnings Release.
2020-02-14 English
Regulatory Filings 2020
Regulatory Filings
2020-01-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.